Widely used:Recently Viewed
Clear All
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$1,885 Mln
P/E Ratio
--
P/B Ratio
18.78
Industry P/E
--
Debt to Equity
-2.09
ROE
-23.05 %
ROCE
-0.4 %
Div. Yield
0 %
Book Value
--
EPS
-0.13
CFO
$14,715.10 Mln
EBITDA
$33,656.00 Mln
Net Profit
$-7,588.70 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Bausch Health Companies (BHC)
| -36.72 | -28.67 | -33.33 | -41.65 | -38.73 | -21.33 | -30.96 |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Bausch Health Companies (BHC)
| 27.71 | -77.25 | 32.74 | -30.48 | 61.99 | -11.06 | 43.11 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 3.15 | 585.93 | -- | -68.76 | |
| 1.19 | 216.22 | -- | -83.54 | |
| 1.77 | 677.08 | 16.09 | 3.8 | |
| 1.40 | 347.35 | -- | -8.08 |
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic... pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; dermatology products; generic pharmaceutical products; and dentistry products. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada. Read more
CEO & Director
Mr. Thomas J. Appio
CEO & Director
Mr. Thomas J. Appio
Headquarters
Laval, QC
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Bausch Health Companies Inc (BHC) stood at $ 26,523 Mln as on 31-Dec-24
The share price of Bausch Health Companies Inc (BHC) is $5.10 (NYSE) as of 17-Apr-2025 16:18 EDT. Bausch Health Companies Inc (BHC) has given a return of -38.73% in the last 3 years.
Bausch Health Companies Inc (BHC) has a market capitalisation of $ 1,885 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Bausch Health Companies Inc (BHC) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Bausch Health Companies Inc (BHC) and enter the required number of quantities and click on buy to purchase the shares of Bausch Health Companies Inc (BHC).
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; dermatology products; generic pharmaceutical products; and dentistry products. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
The CEO & director of Mr. Thomas J. Appio. is Bausch Health Companies Inc (BHC), and CFO & Sr. VP is Mr. Thomas J. Appio.
There is no promoter pledging in Bausch Health Companies Inc (BHC).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
75
|
|
|
69
|
|
|
49
|
|
|
45
|
| Bausch Health Companies Inc. (BHC) | Ratios |
|---|---|
|
Return on equity(%)
|
4
|
|
Operating margin(%)
|
16.34
|
|
Net Margin(%)
|
-0.48
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Bausch Health Companies Inc (BHC) was $0 Mln.
$0.60
(
